Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Judit Nyirady"'
Autor:
Steven R. Feldman, Lawrence Green, Alexa B. Kimball, Kimberly Siu, Yang Zhao, Vivian Herrera, Judit Nyirady, Andrew F. Alexis
Publikováno v:
Journal of Dermatological Treatment, Vol 28, Iss 8, Pp 716-721 (2017)
Introduction: Scalp psoriasis adversely affects patients’ lives and is often resistant to treatment; however, it has not been a major focus of a clinical study. This analysis assessed the effect of secukinumab on patient-reported outcomes (PRO) of
Externí odkaz:
https://doaj.org/article/b5e70c2a87a94e739fe767c40d06d7d5
Autor:
Neil J. Korman, Howard Sofen, Scott Fretzin, Phoebe Rich, Yang Zhao, Vivian Herrera, Judit Nyirady, Nicole Williams, Margaret Mordin, Stephen Tyring
Publikováno v:
Journal of Dermatological Treatment, Vol 28, Iss 5, Pp 384-389 (2017)
Background: Psoriasis can greatly impact patients’ lives, influencing what clothing they wear and impairing their sexual functioning. Objective: To provide a detailed comparison of the impact of secukinumab vs. etanercept on enabling patients with
Externí odkaz:
https://doaj.org/article/0e3f3381d5894ba38424f319b7217a8d
Autor:
April W. Armstrong, Steven R. Feldman, Neil J. Korman, Xiangyi Meng, Adriana Guana, Judit Nyirady, Vivian Herrera, Yang Zhao
Publikováno v:
Journal of Dermatological Treatment, Vol 28, Iss 3, Pp 200-205 (2017)
Background: Conventional measurements for assessing psoriasis treatment effects capture improvements at fixed, pre-specified timepoints, failing to account for cumulative clinical benefit over time. Objective: Explore the innovative concept of “cum
Externí odkaz:
https://doaj.org/article/f4bf64d093f74e058ccfc48746f6da17
Autor:
Joel Schlessinger, Xiangyi Meng, Adriana Guana, Ronald Vender, Judit Nyirady, Yves Poulin, Richard G. Langley, Ellen Frankel, David M. Pariser
Publikováno v:
Dermatology and Therapy
Introduction Demographic and disease characteristics may impact response to psoriasis therapies. The objective of this study is to explore the safety and efficacy profile of secukinumab in North American (NA) versus non-NA patients with moderate to s
Autor:
Judit Nyirady, Kimberly Siu, Kristina Callis Duffin, Jerry Bagel, Angela Moore, Laura K. Ferris, Mark Lebwohl, Jennifer Steadman, Farid Kianifard
Publikováno v:
Journal of the American Academy of Dermatology. 77:667-674
Moderate-to-severe scalp psoriasis has not been evaluated in prospective trials of patients without moderate-to-severe body psoriasis.Evaluate the efficacy and safety of secukinumab in moderate-to-severe scalp psoriasis.In this 24-week, double-blind,
Publikováno v:
Journal of Clinical Pharmacology
Secukinumab is a human monoclonal antibody with demonstrated efficacy for moderate to severe psoriasis; it binds to and neutralizes interleukin (IL)‐17A. The pharmacokinetic (PK) parameters of secukinumab were best described by a 2‐compartment mo
Autor:
David M. Pariser, Redzinaldas Narbutas, Alice B. Gottlieb, Vivian Herrera, Yang Zhao, Judit Nyirady, Bruce Strober, Mark Lebwohl, Roland Kaufmann, Lori McLeod, Boni E. Elewski, Dawn Odom
Publikováno v:
Journal of Psoriasis and Psoriatic Arthritis. 2:73-80
Background Psoriasis negatively affects patients’ quality of life. Secukinumab is a human interleukin-17A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis. Objectives The current analysis evaluated the benefits of secuk
Autor:
Neil J. Korman, Scott Fretzin, Howard Sofen, Nicole Williams, Yang Zhao, Margaret Mordin, Phoebe Rich, Stephen K. Tyring, Judit Nyirady, Vivian Herrera
Publikováno v:
Journal of Dermatological Treatment. 28:384-389
Psoriasis can greatly impact patients' lives, influencing what clothing they wear and impairing their sexual functioning.To provide a detailed comparison of the impact of secukinumab vs. etanercept on enabling patients with psoriasis to have more nor
Autor:
Bruce Strober, Bárður Sigurgeirsson, Georg Popp, Rodney Sinclair, James Krell, Sigitas Stonkus, Marcis Septe, Boni E. Elewski, Alice B. Gottlieb, Yang Zhao, Vivian Herrera, Margaret Mordin, Dawn Odom, Charis Papavassilis, Judit Nyirady, Mark Lebwohl
Publikováno v:
Journal of Psoriasis and Psoriatic Arthritis. 1:167-174
Background Secukinumab, a fully human anti-interleukin 17A monoclonal antibody, has demonstrated rapid, strong, and sustained efficacy in moderate-to-severe plaque psoriasis. Objective To measure treatment effect on psoriasis-related itching, pain, a
Autor:
Xiangyi Meng, Neil J. Korman, April W. Armstrong, Steven R. Feldman, Judit Nyirady, Yang Zhao, Vivian Herrera, Adriana Guana
Publikováno v:
Journal of Dermatological Treatment. 28:200-205
Background: Conventional measurements for assessing psoriasis treatment effects capture improvements at fixed, pre-specified timepoints, failing to account for cumulative clinical benefit over time.Objective: Explore the innovative concept of “cumu